Session 9-Oral AbstractsTB and Opportunistic DiseasesMonday, 10-11 am;Ballroom B-C

Paper # 38International Randomized Trial of Immediate vs Early ART in HIV+Patients Treated for TB: ACTG 5221 STRIDE StudyDiane Havlir*1, P Ive2, M Kendall3, A Luetkemeyer1, S Swindells4, J Kumwenda5, S Qasba6, E Hogg7, J Anderson3, I Sanne2, and A5521 Team1Univ of California, San Francisco, US;2Univ of the Witwatersrand, Johannesburg, South Africa;3Harvard Sch of Publ Hlth, Boston, MA, US;4Univ of Nebraska, Omaha, US;5Johns Hopkins Univ Res Project, Blantyre, Malawi;6NIH, Bethesda, MD, US; and7Social & Sci Systems, Inc, Silver Spring, MD, USBackground:Initiation of ART in patients currently treated for pulmonary TB reduces mortality. Optimal timing of ART initiation for TB/HIV co-infected patients of varying levels of immune compromise has not been established.Methods:AIDS Clinical Trials Group (ACTG) 5221 was an open-label, randomized, strategy study comparing immediate ART (2 weeks after TB treatment start) to early ART (8 to 12 weeks) among HIV+subjects with CD4+cells